Biomica Signs an Agreement with Weizmann Institute of Science to Develop a Selective Treatment Against Antibiotic-Resistant Bacteria

Biomica Signs an Agreement with Weizmann Institute of Science to Develop a Selective Treatment Against Antibiotic Resistant Bacteria

Shots:

  • Biomica collaborated with Weizmann Institute of Science to develop a selective treatment against antibiotic-resistant strains of Staphylococcus aureus infection, targeting a specific microbe while maintaining the microbiome of the patients’ gut.
  • Biomica has in-licensed IP rights of Prof. Ada E. Yonath’s work and discoveries in the high-resolution crystal structure, allowing a high degree of specificity with Biomica’s computational technology, enabling the development of selective, narrow-spectrum antibiotics
  • The collaboration will put Prof. Yonath’s achievements into practice, to resolve a substantial, unmet clinical need, by developing a highly selective solution to the resistance of Staphylococcus aureus

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Linkedin